Table 1.
Overview of criteria for CPG recommendations for older people*
| Inclusion of information related to: | ||
|---|---|---|
| 1. Available evidence primary CVD prevention for older people | 2. Barriers to implementation of the CPG for older people | 3. Tailoring treatment to older people context and preferences |
| a. Evidence potential benefits/harms | a. Risk assessment complexity (e.g. measurement issues) | a. Patient preferences/values |
| b. Knowledge gaps | b. Risk management complexity (e.g. feasibility treatment targets) | b. Family preferences/values |
| c. Time needed to treat to benefit in context of life expectancy | c. Patient context (e.g. quality of life, life expectancy, comorbidities) | |
| d. Meaningfulness outcomes for older people | d. Weighing benefits/harms | |
| e. Treatment adherence issues | e. Therapy prioritization | |
| f. Cognitive status | ||
| g. Social support/caregiver burden | ||